Fredun Pharmaceuticals Intrinsic Value
Fredun Pharmaceuticals (FREDUN) median intrinsic value is ₹1026.67 from 9 valuation models (range ₹391–₹2607), vs current price ₹1303.50 — -21.2% downside (Trading Above Calculated Value), margin of safety -27.0%. Check FREDUN market capitalization to track the company's total market size over time.
FREDUN Valuation Methods Summary — DCF, Graham Number & P/E
Fredun Pharmaceuticals intrinsic value across 9 models vs current price ₹1303.50 — upside/downside and value range per method. See FREDUN P/B ratio to compare market price against book value per share.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹1733.60 | ₹1386.88 - ₹2080.32 | +33.0% | EPS: ₹78.80, Sector P/E: 22x |
| Book Value Method | asset | ₹926.67 | ₹834.00 - ₹1019.34 | -28.9% | Book Value/Share: ₹463.33, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹2607.00 | ₹2346.30 - ₹2867.70 | +100.0% | Revenue/Share: ₹1400.00, P/S: 2.0x |
| EBITDA Multiple Method | earnings | ₹1733.33 | ₹1560.00 - ₹1906.66 | +33.0% | EBITDA: ₹104.00Cr, EV/EBITDA: 10x |
| PEG Ratio Method | growth | ₹504.32 | ₹453.89 - ₹554.75 | -61.3% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹1217.46 | ₹1095.71 - ₹1339.21 | -6.6% | Revenue Growth: 6.0%, Adj P/E: 15.5x |
| ROE Based Valuation | profitability | ₹1026.67 | ₹924.00 - ₹1129.34 | -21.2% | ROE: 15.8%, P/E Multiple: 14x |
| Graham Defensive Method | conservative | ₹906.36 | ₹815.72 - ₹997.00 | -30.5% | EPS: ₹78.80, BVPS: ₹463.33 |
| Dividend Yield Method | dividend | ₹391.05 | ₹351.94 - ₹430.16 | -70.0% | DPS: ₹0.70, Target Yield: 2.5% |
FREDUN Intrinsic Value vs Market Price — All Valuation Models
Fredun Pharmaceuticals fair value range ₹391–₹2607 vs current market price ₹1303.50 across 9 valuation models. For current market price and key ratios, visit FREDUN share price screener.
FREDUN Intrinsic Value Analysis — Undervalued or Overvalued?
Fredun Pharmaceuticals median intrinsic value ₹1026.67, current price ₹1303.50 — Trading Above Calculated Value by 21.2%, margin of safety -27.0%.
What is the intrinsic value of FREDUN?
Based on our comprehensive analysis using 9 different valuation methods, the estimated intrinsic value of Fredun Pharmaceuticals (FREDUN) is ₹1026.67 (median value). With the current market price of ₹1303.50, this represents a -21.2% variance from our estimated fair value.
The valuation range spans from ₹391.05 to ₹2607.00, indicating ₹391.05 - ₹2607.00.
Is FREDUN undervalued or overvalued?
Based on our multi-method analysis, Fredun Pharmaceuticals (FREDUN) appears to be trading above calculated value by approximately 21.2%.
FREDUN Financial Health — Key Ratios vs Industry Benchmarks
Fredun Pharmaceuticals financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 7.43 | Industry Standard: 2.0+ | Above 2.0 | Measures short-term liquidity capacity |
| Return on Equity | 15.8% | Industry Standard: 15%+ | Above 15% | Measures shareholder return efficiency |
| Operating Margin | 12.0% | Industry Standard: 20%+ | Above 10% | Indicates operational efficiency level |
| Asset Turnover Ratio | 1.31x | Industry Standard: 1.0x+ | Above 1.0x | Measures asset utilization efficiency |
FREDUN Cash Flow Quality — Operating & Free Cash Flow
Fredun Pharmaceuticals operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2026 | ₹12 Cr | ₹-25 Cr | Positive Operating Cash Flow | 6/10 |
| March 2025 | ₹-17 Cr | ₹-20 Cr | Negative Cash Flow | 3/10 |